# Oxford University

Type: Company

Source: GetYourBrief — https://getyourbrief.com/entity/oxford-university
Canonical HTML page: https://getyourbrief.com/entity/oxford-university

## Timeline

- **2026-07-27**: 3,000 Cases Milestone — Total cases reach 3,075, with 1,354 deaths, amid healthcare strikes and calls for accelerated countermeasure development.
- **2026-07-24**: First Experimental Vaccine Volunteer Dosed — Oxford University reports that the first volunteer group has received its candidate vaccine specifically targeting Bundibugyo.
- **2026-07-15**: 2,000 Cases Surpassed — Cumulative confirmed cases exceed 2,000, with rapid spread noted in conflict zones.
- **2026-07-05**: WHO reveals outbreak toll — WHO Director-General announces 1,400+ cases and 438 deaths, confirming the trial's start and expressing hope for effective therapies.
- **2026-07-02**: Trial launch and first enrollment — Researchers begin the first-ever Ebola treatment trial for Bundibugyo virus at Bunia's Evangelical Medical Center, enrolling the first participant to evaluate remdesivir and MBP134.
- **2026-05-15**: Outbreak Declared — DR Congo announces its 17th Ebola outbreak, identifying the Bundibugyo strain as the cause.

## Recent coverage (2 stories, network-wide)

### Ebola Outbreak Tops 3,000 Cases, Oxford Starts Clinical Trial for Bundibugyo Vaccine
2026-07-27 09:57:21 · Sector: bio · Sentiment: Strongly negative · Impact: 7/10 · Sources: 2

DRC’s 17th Ebola outbreak has exploded to 3,075 cases and 1,354 deaths, with 1,000 new infections in just 10 days. The Bundibugyo strain has no approved vaccine or treatment, igniting a biotech race: Oxford University has dosed its first volunteer with an experimental vaccine, while other candidates are fast-tracked, creating high-stakes opportunities for pharma developers.
Full story: https://getbiobrief.com/story/ebola-outbreak-3000-cases-bundibugyo-vaccine-clinical-trial

### Congo Ebola Trial Enrolls First Patient Amid 438 Deaths
2026-07-25 17:51:47 · Sector: health · Sentiment: Positive · Impact: 6/10 · Sources: 1

A WHO-backed clinical trial in conflict-hit Congo is testing remdesivir and MBP134 for the Bundibugyo strain, spotlighting the extreme operational challenges of providing care and conducting research in fragile health systems.
Full story: https://gethealthbrief.com/story/congo-ebola-trial-health-systems

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.